Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.

Landy S, Munjal S, Brand-Schieber E, Rapoport AM.

J Headache Pain. 2018 Aug 15;19(1):69. doi: 10.1186/s10194-018-0881-z.

2.

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.

Landy S, Munjal S, Brand-Schieber E, Rapoport AM.

J Headache Pain. 2018 Aug 15;19(1):70. doi: 10.1186/s10194-018-0882-y.

3.

Psychological flexibility in migraine: A study of pain acceptance and values-based action.

Foote HW, Hamer JD, Roland MM, Landy SR, Smitherman TA.

Cephalalgia. 2016 Apr;36(4):317-24. doi: 10.1177/0333102415590238. Epub 2015 Jun 10.

PMID:
26063726
4.

So you want to be a Specialty Doctor.

Landy S.

Ulster Med J. 2015 Jan;84(1):71. No abstract available.

5.

Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post-hoc analysis of four randomized trials of eletriptan 40 mg.

Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E.

Cephalalgia. 2014 Apr;34(5):376-81. doi: 10.1177/0333102413512035. Epub 2013 Nov 21.

PMID:
24265285
6.

Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.

Landy SH, Cady RK, Nelsen A, White J, Runken MC.

Headache. 2014 Apr;54(4):640-54. doi: 10.1111/head.12214. Epub 2013 Sep 19.

PMID:
24102322
7.

Sumatriptan/naproxen sodium combination versus its components administered concomitantly for the acute treatment of migraine: a pragmatic, crossover, open-label outcomes study.

Landy S, Hoagland R, Hoagland D, Saiers J, Reuss G.

Ther Adv Neurol Disord. 2013 Sep;6(5):279-86. doi: 10.1177/1756285613499788.

8.

Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study.

Almas M, Tepper SJ, Landy S, Schweizer E, Ramos E.

Cephalalgia. 2014 Feb;34(2):126-35. doi: 10.1177/0333102413500726. Epub 2013 Aug 14.

PMID:
23946318
9.

A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.

Landy SH, Turner IM, Runken MC, Lee M, Sulcs E, Bell CF.

Headache. 2013 Jul-Aug;53(7):1134-46. doi: 10.1111/head.12140. Epub 2013 Jun 14.

PMID:
23773016
10.

An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.

Landy SH, Tepper SJ, Wein T, Schweizer E, Ramos E.

Headache. 2013 Jan;53(1):118-125. doi: 10.1111/j.1526-4610.2012.02295.x. Epub 2012 Nov 13.

PMID:
23148799
11.

Does health information exchange reduce unnecessary neuroimaging and improve quality of headache care in the emergency department?

Bailey JE, Wan JY, Mabry LM, Landy SH, Pope RA, Waters TM, Frisse ME.

J Gen Intern Med. 2013 Feb;28(2):176-83. doi: 10.1007/s11606-012-2092-7. Epub 2012 May 31.

12.

Examining the interrelationship of migraine onset, duration, and time to treatment.

Landy SH, Runken MC, Bell CF, Higbie RL, Haskins LS.

Headache. 2012 Mar;52(3):363-73. doi: 10.1111/j.1526-4610.2011.02029.x. Epub 2011 Nov 11.

PMID:
22077159
13.

Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention.

Landy S, Hoagland R, Hoagland NA.

Headache. 2012 Jan;52(1):133-9. doi: 10.1111/j.1526-4610.2011.01992.x. Epub 2011 Aug 29.

PMID:
21883200
14.

Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response survey.

Cady R, Banks J, Nett RB, Goldstein J, Bennett N, Turner IM, Ruoff GE, Landy SH, Farmer K, Juhász M, Tarrasch J, Runken MC.

Headache. 2011 Jun;51(6):961-70. doi: 10.1111/j.1526-4610.2011.01912.x. Epub 2011 May 17.

PMID:
21592098
15.

Time to recovery in patients with acute painful musculoskeletal conditions treated with extended-release or immediate-release cyclobenzaprine.

Landy S, Altman CA, Xie F.

Adv Ther. 2011 Apr;28(4):295-303. doi: 10.1007/s12325-011-0008-2. Epub 2011 Mar 18.

PMID:
21424735
16.

Assessing the impact of migraine onset on work productivity.

Landy SH, Runken MC, Bell CF, Higbie RL, Haskins LS.

J Occup Environ Med. 2011 Jan;53(1):74-81. doi: 10.1097/JOM.0b013e31812006365.

PMID:
21187794
17.

[A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].

Auboire L, Landy S, Perrot JY, Maïza D, Le Hello C.

J Mal Vasc. 2010 Feb;35(1):35-7. doi: 10.1016/j.jmv.2009.10.003. Epub 2009 Dec 2. Review. French.

PMID:
19959302
18.

Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.

Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D.

Headache. 2009 Jul;49(7):971-82. doi: 10.1111/j.1526-4610.2009.01458.x. Epub 2009 May 27.

PMID:
19486178
19.

The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research.

Burton WN, Landy SH, Downs KE, Runken MC.

Mayo Clin Proc. 2009 May;84(5):436-45. doi: 10.1016/S0025-6196(11)60562-4. Review.

20.

Fixed-dose Sumatriptan/Naproxen Sodium Compared with each Monotherapy Utilizing the Novel Composite Endpoint of Sustained Pain-free/no Adverse Events.

Landy S, White J, Lener SE, McDonald SA.

Ther Adv Neurol Disord. 2009 May;2(3):135-41. doi: 10.1177/1756285609102769.

21.

Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.

Newman LC, Cady RK, Landy S, O'Carroll P, Kwong WJ, Burch SP, Nelsen AC, McDonald SA.

Int J Clin Pract. 2008 Dec;62(12):1889-99. doi: 10.1111/j.1742-1241.2008.01935.x.

23.

Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.

Mannix LK, Savani N, Landy S, Valade D, Shackelford S, Ames MH, Jones MW.

Headache. 2007 Jul-Aug;47(7):1037-49.

PMID:
17635595
24.

Clarification of developing and established clinical allodynia and pain-free outcomes.

Landy SH, McGinnis JE, McDonald SA.

Headache. 2007 Feb;47(2):247-52.

PMID:
17300364
26.

Migraine: a better way to recognize and treat it.

Landy SH, Kwong WJ, Hutchinson S, Roselli A, Burch SP.

J Fam Pract. 2006 Dec;55(12):1038-47.

PMID:
17137539
27.
28.

Migraine treatment throughout the lifecycle.

Landy SH, Lobo BL.

Expert Rev Neurother. 2005 May;5(3):343-53. Review.

PMID:
15938667
29.

Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan.

Landy SH, McGinnis JE, McDonald SA.

Headache. 2005 Apr;45(4):346-9.

PMID:
15836571
30.

Selective serotonin reuptake inhibitors for migraine prophylaxis.

Landy S, McGinnis J, Curlin D, Laizure SC.

Headache. 1999 Jan;39(1):28-32.

PMID:
15613191
31.

Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine.

Landy S, Savani N, Shackelford S, Loftus J, Jones M.

Int J Clin Pract. 2004 Oct;58(10):913-9.

PMID:
15587768
33.
34.

Challenging or difficult headache patients.

Landy SH.

Prim Care. 2004 Jun;31(2):429-40, viii. Review.

PMID:
15172517
35.

Central sensitisation and cutaneous allodynia in migraine: implications for treatment.

Landy S, Rice K, Lobo B.

CNS Drugs. 2004;18(6):337-42. Review.

PMID:
15089101
36.

Migraine throughout the life cycle: treatment through the ages.

Landy S.

Neurology. 2004 Mar 9;62(5 Suppl 2):S2-8. Review.

PMID:
15007158
37.

Brief psychoeducational parenting program: an evaluation and 1-year follow-up.

Bradley SJ, Jadaa DA, Brody J, Landy S, Tallett SE, Watson W, Shea B, Stephens D.

J Am Acad Child Adolesc Psychiatry. 2003 Oct;42(10):1171-8.

PMID:
14560166
38.

Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine.

Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M.

Obstet Gynecol. 2003 Oct;102(4):835-42.

PMID:
14551015
39.

Migraine, Midrin, and Imitrex.

Landy S, Richardson M, O'Quinn S.

Headache. 2002 Apr;42(4):322-3; author reply 323-4. No abstract available.

PMID:
12010397
40.

Maternal attachment and sensitivity in an at-risk sample.

Oyen AS, Landy S, Hilburn-Cobb C.

Attach Hum Dev. 2000 Sep;2(2):203-17.

PMID:
11707911
41.

Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.

Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG, Watson C, Jöbsis M, Batenhorst A, O'Quinn S.

Headache. 2001 Mar;41(3):248-56.

PMID:
11264684
42.

[Prevalence of duplex ultrasonography detectable venous thrombosis in patients with suspected or acute pulmonary embolism].

Barrellier MT, Lezin B, Landy S, Le Hello C.

J Mal Vasc. 2001 Feb;26(1):23-30. Review. French.

PMID:
11240526
43.

Working with parents of aggressive preschoolers: an integrative approach to treatment.

Menna R, Landy S.

J Clin Psychol. 2001 Feb;57(2):257-69. Review.

PMID:
11180151
44.

Pressure, heat, and cold help relieve headache pain.

Landy SH, Griffin B.

Arch Fam Med. 2000 Sep-Oct;9(9):792-3. No abstract available.

PMID:
11031383
45.

Cosmological Parameters from the Eigenmode Analysis of the Las Campanas Redshift Survey.

Matsubara T, Szalay AS, Landy SD.

Astrophys J. 2000 May 20;535(1):L1-L4.

PMID:
10828994
46.

Symptomatic pharmacotherapy of migraine.

Lobo BL, Cooke SC, Landy SH.

Clin Ther. 1999 Jul;21(7):1118-30. Review.

PMID:
10463512
47.

Divalproex sodium--review of prophylactic migraine efficacy, safety and dosage, with recommendations.

Landy SH, McGinnis J.

Tenn Med. 1999 Apr;92(4):135-6. Review. No abstract available.

PMID:
10194980
48.

X-inactivation and marker studies in three families with incontinentia pigmenti: implications for counselling and gene localisation.

Woffendin H, Jakins T, Jouet M, Stewart H, Landy S, Haan E, Harris A, Donnai D, Read A, Kenwrick S.

Clin Genet. 1999 Jan;55(1):55-60.

PMID:
10066033
49.
50.

Linkage analysis in 16 families with incontinentia pigmenti.

Jouet M, Stewart H, Landy S, Yates J, Yong SL, Harris A, Garret C, Hatchwell E, Read A, Donnai D, Kenwrick S.

Eur J Hum Genet. 1997 May-Jun;5(3):168-70.

PMID:
9272741

Supplemental Content

Support Center